FDA approves valsartan generic as shortages develop

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Olhakozachenko)
(Image: Getty/Olhakozachenko)

Related tags valsartan Sartan Fda

US FDA announces that a new generic for valsartan will reach the market, after prioritising the review of the product to alleviate shortages resulting from recalled products.

The newly approved generic version of valsartan will be produced by Alkem Laboratories, an Indian company headquartered in Mumbai.

The US Food and Drug Administration (FDA) stated that it had prioritised the review of Alkem’s drug application to provide an additional supply of valsartan medication, as a number of batches were recalled due to the discovery of contamination in sartan products last year.

The European Medicines Agency originally discovered valsartan manufactured by Zhejiang Huahai were contaminated with N-Nitrosodimethylamine in July 2018 – a finding which prompted a global recall​.

From this starting point, the investigation widened to include further sartan products​ and manufacturers​, as well as uncovering contamination with N-Nitrosodiethylamine and further nitrosamines​.

The scale of the recalls sees the FDA expediting the review of products involved, which extends to losartan medication.

Outgoing FDA Commissioner​, Scott Gottlieb said, “We’ll continue to work with manufacturers so that more medicines like valsartan, that belong to a class of drugs called angiotensin II receptor blockers, can be approved that are free of nitrosamine impurities to continue to address this ongoing shortage.”

Regarding Alkem’s manufacturing processes, the FDA stated that it had required the company to utilise testing methods that demonstrated its product did not contain any nitrosamine impurities.

In January 2019​, the FDA released its conclusions on how the impurities had been formed during the manufacturing process, suggesting that it could result from the reuse of materials, such as solvents.

The agency stated that is currently working on implementing new requirements that will “guard against the development of these impurities in drugs.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more